Specific oral contraceptive use and venous thromboemolism resulting in hospital admission

New Zealand Medical Journal

Volumn 117, Issue 1206, 2004, Pages

  Heuser, Patricia ^a   Tonga, Katrina ^b   Hopkins, Raewyn ^c   Henderson, Marissa ^b   Weatherall, Mark ^b   Metcalfe, Scott ^d   Beasley, Richard ^a,e  

^a MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c GREEN LANE HOSPITAL   (New Zealand)

^d Pharmaceutical Management Agency   (New Zealand)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; DESOGESTREL; DIANE; ESTELLE 35; ETHINYLESTRADIOL; ETYNODIOL DIACETATE; GESTODENE; LEVONORGESTREL; MESTRANOL; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DRUG USE; FEMALE; FREQUENCY ANALYSIS; HOSPITAL ADMISSION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; PRESCRIPTION; RADIODIAGNOSIS; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM;

EID: 27244460190     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Vandenbroucke JP, Rosing J, Bloemenkamp KWM, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med. 2001;344:1527-35.
2. Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestogen components. Lancet. 1995;346:1589-93.
3. Spitzer WO. The aftermath of a pill scare: regression to reassurance. Hum Reprod Update. 1999;5:736-45.
4. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet. 1995;346:1575-82.
5. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ. 2001;323:1-9.
6. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet. 1995;346:1582-8.
7. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet. 2001;358:1427-9.
8. Parkin L, Skegg DC, Wilson M, et al. Oral contraceptives and fatal pulmonary embolism. Lancet. 2000;355:2133-4.
9. Goldhaber SZ. Pulmonary embolism. Lancet. 2004;363:1295-305.
10. Van Grootheest K, Vrieling T. Thromboembolism associated with the new contraceptive Yasmin. BMJ. 2003;326:257.
11. New Zealand Medicines and Medical Devices Safety Authority. Oral contraceptives and blood clots. Wellington: MedSafe, Ministry of Health; 2002. Available online. URL: http://www.gp.org.nz/outbox_docs/obx_previews/a4_obx_previews/oc_vte.pdf Accessed November 2004.
12. World Health Organisation. Improving access to quality care in family planning. Medical eligibility criteria for contraceptive use. Second edition. Geneva: WHO; 2000.